120 related articles for article (PubMed ID: 8789360)
1. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
Artázcoz Sanz MT; Viñes Rueda JJ
Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
[TBL] [Abstract][Full Text] [Related]
2. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I
Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809
[TBL] [Abstract][Full Text] [Related]
3. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
Martínez-Suárez MM; Blázquez-Menes B
Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
[TBL] [Abstract][Full Text] [Related]
4. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
[TBL] [Abstract][Full Text] [Related]
5. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
6. [The evolution of use of anti-Parkinson drugs in Spain].
Montané E; Vallano Ferraz A; Castel JM
Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509
[TBL] [Abstract][Full Text] [Related]
7. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004).
Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG
Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence of Parkinson disease in an urban area of the Ciudad de La Habana province, Cuba. Door-to-door population study].
Giroud Benítez JL; Collado-Mesa F; Esteban EM
Neurologia; 2000; 15(7):269-73. PubMed ID: 11075574
[TBL] [Abstract][Full Text] [Related]
9. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838
[TBL] [Abstract][Full Text] [Related]
10. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
Harris MA; Koehoorn M; Teschke K
Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
[TBL] [Abstract][Full Text] [Related]
11. [Incidence of idiopathic and secondary Parkinson disease in Navarre. Population-based case registry].
Viñes JJ; Larumbe R; Gaminde I; Artázcoz MT
Neurologia; 1999 Jan; 14(1):16-22. PubMed ID: 10079687
[TBL] [Abstract][Full Text] [Related]
12. Population prevalence and incidence of Parkinson's disease in an Australian community.
Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM
Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Parkinson's disease in Spain.
Grandas F; Kulisevsky J
Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
[TBL] [Abstract][Full Text] [Related]
14. Punding prevalence in Parkinson's disease.
Miyasaki JM; Al Hassan K; Lang AE; Voon V
Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
Fischer PA
J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
18. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
19. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.
Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV
Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
